on
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
Audrey Schupp, Chief Executive Officer
Ms. Audrey Schupp has been in the pharmaceutical industry for 25+ years. She began her career in the Quality Control Microbiology department of a life sciences company under consent decree. Within a year of her employment, she was chosen to be a team member of a newly created Quality Assurance department dedicated to working closely with Operations to elevate company Quality standards and extract the company from the consent decree. Within six months of working within this new group, she was promoted to Group Lead for a team of ten Quality Assurance supervisors operating in the compounding, filling, and lyophilization areas. This unique opportunity allowed her to witness how Quality and Operations could be structured to affect real change and allowed her to participate in the development of Quality Systems aimed at building Quality principles into the manufacturing and facility operations. Harmonizing Quality and Manufacturing has been her guiding principle throughout her career.
Ms. Schupp believes that in order to compile a robust CMC submission, Operations, Quality Assurance, and Regulatory Affairs must work closely and in harmony. She has held both Quality and Operations roles; however, she understands that strong knowledge of regulatory guidance documents (FDA, ICH, EU GMPs, Canadian GMPs, Japanese GMPs, ISO) is critical to ensure that quality is built into the process, to ensure that good decisions are being made, and to ensure the CMC portions of the submissions are complete and accurate.
Ms. Schupp is a skilled CMC technical transfer expert and submission technical writer (IND, NDA, ANDA, BLA, PAS, CBE-30, CBE-0). She has been responsible for leading the technical writing of the CMC sections for more than thirty regulatory filings, including complete CMC sections for NDA, BLA, and drug-device submissions. She has been responsible for technical transfers requiring a complete overhaul of the CMC sections, numerous technical transfers requiring minor to moderate revisions to the existing filing, and has served as the subject matter expert for FDA Prior Approval Inspections.
Ms. Schupp has been in Quality and Manufacturing roles in both traditional and virtual pharmaceutical companies. Her strengths are managing vendor relationships, pre-IND and early phase IND submissions, technical transfers, and highly challenging routine production environments. She has worked directly in technical roles as the Subject Matter Expert for liquid, powder, ointment, ampoule, pre-filled syringe, and lyophilized sterile/aseptic products; ophthalmic products; nasal sprays; transdermal and topical products; solid dosage forms; medical devices; and combination products. She has led inter-disciplinary project teams through complicated technical transfer programs, Quality Systems remediation programs, and Quality by Design product strategies. She has extensive expertise in due diligence audits, quality audits, suppler qualification, and vendor sourcing.
In 2014, Audrey Schupp began her own consulting business aimed at assisting pharmaceutical, biotechnology, and medical device companies in achieving their submission goals. CMC Turnkey Solutions works with small, virtual, niche innovative companies to provide regulatory strategy support, submission preparation, CMC Quality and Operations oversight, and supply chain management to ensure product is developed and manufactured under Quality First principles.
Adriana Stihi, CMC Scientific Advisor
Mrs. Adriana Stihi graduated from the most prestigious engineering and technology university in Romania, her homeland, with a Masters degree in Biochemistry. After working for more than 10 years on several biotechnology and biomedical research projects, Adriana moved with her family to the United States and started her new career in the pharmaceutical industry.
For 30+ years, Adriana has held positions of increasing responsibility in R&D, QC and QA within branded and generic, traditional and virtual pharmaceutical companies. Adriana began her career in the analytical chemistry field. As one of the first users of the Waters Alliance HPLC system launched in 1996, she worked with field engineers on improving the end-user experience. Only a couple of years into her career, Adriana was recognized for her keen expertise and attention to detail, being selected for an interdepartmental team for audit of data generated for regulatory submissions. This unique opportunity allowed her to gain a strong understanding of quality and risk management systems.
Over the years, Adriana had the opportunity to work on all stages of drug product’s lifecycle: pharmaceutical development, product launch, technology transfer, commercial manufacturing, and post-approval commitments. She has been responsible and successfully completed analytical laboratory setups, technology transfers, development and validation activities, internal and external quality audits, applying her extensive knowledge of Quality Management System and LEAN strategies. As quality manager for development and commercial activities at contract manufacturing sites in US, Canada and EU, Adriana lead technical and compliance activities, and authored key CMC sections for numerous regulatory submissions.
As a culmination of her career, Adriana served as Quality Director of a start-up dietary supplements manufacturing company that developed and patented the design and technology for a novel 2-in-1 capsule product. In this role, she created and maintained quality standards and policies, product quality documentation, supplier qualification programs, quality agreements and contracts, to support batch release and final product commercialization in compliance with GMP and FDA regulations.
In 2019, Adriana established her own consulting business providing regulatory submission support for small pharmaceutical companies, and began her productive collaboration with CMC Turnkey Solutions as Subject Matter Expert (SME) for all its analytical programs.
David Kosinski, CMC & Supply Chain Consultant
David Kosinski is a strategic technology and regulatory operations Senior Project Manager and advisor with more than two decades of experience leading enterprise portfolios across the Pharmaceutical, Clinical Research, Telecommunications, and Compliance sectors. As a Senior Project Manager, Consultant and transformation leader, he specializes in aligning technology modernization with operational execution, regulatory expectations, and executive business priorities—guiding organizations through complex change, integration, and risk landscapes with precision and measurable outcomes.
David has delivered high-impact advisory support for global sponsors including AbbVie, Merck, Johnson & Johnson, Regeneron, Astellas, and Bristol Myers Squibb, shaping delivery models across Clinical Development, Pharmacovigilance, Regulatory Affairs, Market Access, and Quality systems. He is frequently sought after for his ability to simplify complexity, translate regulatory and data needs into actionable technology plans, and shepherd organizations through readiness for inspection, audit, submission, and commercialization.
With proven expertise in M&A integration, portfolio rationalization, data governance, AI risk modeling, and ERP modernization, David supports executive teams in making informed investment decisions and establishing future-state operating frameworks. His work on high-profile integrations—including AbbVie–Allergan and BMS–Celgene—delivered organizational harmonization, cross-system alignment, and unified governance models that accelerated time-to-value and reduced operational friction.
Earlier in his career, David led enterprise technology portfolios at Verizon Wireless, directing budgets exceeding $100 million and managing global teams of 200+ resources. His tenure included implementation of mission-critical Application Performance Management, cloud modernization, disaster recovery frameworks, and cybersecurity programs that strengthened organizational resilience and 24/7 system integrity.
As a Senior Project Manager, consultant and executive advisor, David partners with C-suite leaders, PMOs, and regulatory stakeholders to drive portfolio investment strategy, risk mitigation, enterprise transformation, and compliance maturity. His hallmark approach blends business clarity, technical rigor, and regulatory foresight—ensuring clients achieve operational stability, inspection readiness, technology adoption, and sustained competitive advantage.
Amanda Broughton, RAC, Regulatory & Quality Consultant
Mrs. Amanda Broughton, RAC, is a distinguished consultant with over 20 years of pharmaceutical industry experience. Her expertise encompasses Regulatory Affairs, Quality Assurance, and Quality Control for drugs and biologics across a broad spectrum of dosage forms and therapeutic areas, with a specialty in sterile parenteral products.
Amanda has an exceptional track record in strategy and execution of high-quality regulatory submissions for both pre- and post-approval phases, including technology transfers and other complex CMC projects. Throughout her career, she has held a variety of roles in consulting, sponsor, and contract manufacturing organizations ranging from small startups to large global companies.
Her pharmaceutical career began on the bench after 4 years in an environmental laboratory, where she gained a solid analytical background. She held Quality Control positions focused on method transfer, validation, and routine testing at a mid-size CMO, giving her the opportunity to build a strong GMP foundation and understanding of quality system principles while participating on multi-disciplinary technical transfer teams. After this, Amanda found her niche in Regulatory Affairs, where she developed expertise in CMC and electronic submissions, lifecycle management, regulatory surveillance, quality documentation, agency inspections, and warning letter remediation.
Amanda has had the opportunity to wear many hats in both the Regulatory and Quality realms as a consultant, site leader, manager, and individual contributor. Her career highlights include implementation of a comprehensive site regulatory strategy, phase-appropriate Quality Management Systems, and GMP inspection readiness initiatives for a startup facility as well as managing CMC technical transfer submissions as a consultant for a Top 5 global pharmaceutical company.
Amanda earned her Regulatory Affairs Certification (RAC-Drugs) in 2023 and holds a Bachelor of Science in Chemistry. She is recognized for her deep understanding of pharmaceutical regulations, committed to continuous learning, and passionate about helping companies achieve regulatory success.
Quality Assurance is the backbone of Good Manufacturing Practices (GMP) and must be incorporated into all aspects of production, testing, packaging/labeling, and distribution. Quality and Risk Management principles are utilized to ensure patient safety and consistency in batch production. Quality by Design (QbD) is the concept of ensuring that Quality Assurance considerations are present and implemented early in development to facilitate smooth scale-up operations from R&D through commercialization. Good Documentation Practices (GDP) support the FDA concept that “If it is not documented, it didn’t happen” and ensures that accurate, legible, contemporaneous (ALCOA+) records are available for all aspects of production and testing. A Right the First Time approach to the project reduces risk, redundancy, and wasted time, money, and resources.
Chemistry, Manufacturing, and Controls (CMC) is a regulatory term used to describe the documentation and processes related to the manufacturing and quality control of pharmaceutical drug products, drug substances, and devices. While Quality Assurance functions to oversee these activities, Technical Operations functions to execute the manufacturing, testing, packaging/labeling, distribution, and stability testing on drug products, drug substances, and devices. CMC begins with assessing a potential drug’s safety and formulation/manufacturability and continues through process and analytical development, scale-up, and commercialization. CMC requirements differ between each stage in a product’s lifecycle. Understanding each stage is essential to assure consistency and quality.
Each phase of the product lifecycle introduces specific CMC requirements to ensure product safety, efficacy, and compliance with regulatory standards. During the Research stage, the focus is on initial characterization and formulation development, while Early Phase Clinical emphasizes process scalability and basic quality controls. As products move into Late Phase Clinical and Registration, more rigorous validation, documentation, and stability testing are required. Commercialization demands robust manufacturing processes, comprehensive quality systems, and ongoing regulatory compliance to maintain consistent product quality.
Business operations support is pivotal in ensuring an organization’s efficiency and effectiveness. It encompasses a range of activities designed to streamline processes, enhance productivity, and optimize resource use. Executive leadership often looks to outside parties for mentoring, strategic planning, and thought partnering to better serve their organization. Short-term staffing for key leadership roles is sometimes required when an extensive search is expected to find the right permanent placement for the position.
